Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Cancer and Oncology›Dysgerminoma
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Dysgerminoma

Cancer and Oncology · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A malignant ovarian neoplasm, thought to be derived from primordial germ cells of the sexually undifferentiated embryonic gonad.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (917 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A malignant ovarian neoplasm, thought to be derived from primordial germ cells of the sexually undifferentiated embryonic gonad. It is the counterpart of the classical seminoma of the testis, to which it is both grossly and histologically identical. Dysgerminomas comprise 16% of all germ cell tumors but are rare before the age of 10, although nearly 50% occur before the age of 20. They are generally considered of low-grade malignancy but may spread if the tumor extends through its capsule and involves lymph nodes or blood vessels. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles and Practice of Oncology, 3d ed, p1646)

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Dysgerminomas; Disgerminoma; Disgerminomas.

Where it fits in the MeSH classification

Broader topics
Germinoma

Research landscape

PubMed indexes 5,694 records tagged with the MeSH heading “Dysgerminoma” (counts retrieved 2026-10-29). 76 of them (1.3%) were published from 2020 onward, and the busiest period so far is through 1999 with 5,340 records.

Reviews account for 413 records (7.3%) and meta-analyses for 1. Randomized controlled trials number 12 (0.2%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 5,340 records; 2000-2009: 143 records; 2010-2019: 135 records; 2020 onward: 76 records5,340through 19991432000-20091352010-2019762020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19995,340
2000-2009143
2010-2019135
2020 onward76
Share of records by publication typeReviews: 7.3 percent; Meta-analyses: 0.0 percent; Randomized controlled trials: 0.2 percentReviews7.3% (413)Meta-analyses0.0% (1)Randomized controlled trials0.2% (12)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 5,694 PubMed records
TypeRecordsShare
Reviews4137.3%
Meta-analyses10.0%
Randomized controlled trials120.2%

Method: PubMed query "Dysgerminoma"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in cancer and oncology

Cancer research spans very different kinds of evidence. Laboratory studies in cell lines and animal models reveal mechanisms but often do not translate to patients. Early-phase trials mainly test safety and dosing, while phase 3 randomized trials and their meta-analyses are the usual basis for treatment conclusions. Outcomes also differ in meaning: tumour shrinkage, progression-free survival and overall survival are not interchangeable, and screening studies can be distorted by lead-time and overdiagnosis. When reading a result, check the cancer type and stage studied, the comparison treatment, and which outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Surveillance following orchidectomy for stage I testicular seminoma
Horwich A, Alsanjari N, A'Hern R, Nicholls J, Dearnaley DP, Fisher C
1992Research article
Design not recorded in structured metadata
138cc by
PMID 1586607 · DOI · PMC1977398
Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers
Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert-De Meyts E, Lothe RA
2007Research article
Design not recorded in structured metadata
88cc by
PMID 17274819 · DOI · PMC1797189
Testicular cancer and antecedent diseases
Swerdlow AJ, Huttly SR, Smith PG
1987Research article
Design not recorded in structured metadata
73cc by
PMID 2880604 · DOI · PMC2001571
Metastasizing dysgerminoma in an inland bearded dragon (Pogona vitticeps)
Schmidt-Ukaj S, Brunthaler R, Gumpenberger M
2024Research article
Design not recorded in structured metadata
0cc by
PMID 39633402 · DOI · PMC11619615

Surveillance following orchidectomy for stage I testicular seminoma [1]

Research article Horwich A, Alsanjari N, A'Hern R, Nicholls J, Dearnaley DP, Fisher C · · 1992 · cited 138 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
An analysis of the primary tumour histopathology was performed on 103 patients managed by orchidectomy and surveillance for stage I seminoma.
Closing excerpt
In view of the difficulties of identifying patients at risk and of detecting early relapse, surveillance for stage I seminoma should remain a research protocol.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (173 words)

An analysis of the primary tumour histopathology was performed on 103 patients managed by orchidectomy and surveillance for stage I seminoma. Patients have been followed for 14-141 months (median 62 months) after orchidectomy. Seventeen patients relapsed, the probability of remaining relapse free at 5 years being 82% (95% confidence intervals, 74%-88%). No patients died of progressive germ cell tumours. The only significant histological factor predicting relapse was the presence of lymphatic and vascular invasion. Four of 42 patients with neither lymphatic or vascular invasion recurred, nine of 53 patients with either lymphatic or vascular invasion recurred and three of eight cases with both lymphatic and vascular invasion recurred (P = 0.05-trend). Though initial recurrence was usually of moderate volume and confined to para-aortic nodes, eight patients were treated with chemotherapy either because of the extent of their initial relapse (four cases), or because of subsequent relapse (four cases). In view of the difficulties of identifying patients at risk and of detecting early relapse, surveillance for stage I seminoma should remain a research protocol.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 1586607 · DOI · PMC1977398

Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers [2]

Research article Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert-De Meyts E, Lothe RA · · 2007 · cited 88 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundOvarian germ cell tumours (OGCTs) typically arise in young females and their pathogenesis remains poorly understood.
Closing excerpt
ConclusionThis study provides new data supporting two distinct but overlapping pathways in OGCT development; one involving spontaneous KIT mutation(s) leading to increased survival and proliferation of undifferentiated oogonia, the other related to presence of Y chromosome material and ensuing gonadal dysgenesis in phenotypic females.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (278 words)

BackgroundOvarian germ cell tumours (OGCTs) typically arise in young females and their pathogenesis remains poorly understood. We investigated the origin of malignant OGCTs and underlying molecular events in the development of the various histological subtypes of this neoplasia.ResultsWe examined in situ expression of stem cell-related (NANOG, OCT-3/4, KIT, AP-2gamma) and germ cell-specific proteins (MAGE-A4, NY-ESO-1, TSPY) using a tissue microarray consisting of 60 OGCT tissue samples and eight ovarian small cell carcinoma samples. Developmental pattern of expression of NANOG, TSPY, NY-ESO-1 and MAGE-A4 was determined in foetal ovaries (gestational weeks 13-40). The molecular genetic part of our study included search for the presence of Y-chromosome material by fluorescence in situ hybridisation (FISH), and mutational analysis of the KIT oncogene (exon 17, codon 816), which is often mutated in testicular GCTs, in a subset of tumour DNA samples. We detected a high expression of transcription factors related to the embryonic stem cell-like pluripotency and undifferentiated state in OGCTs, but not in small cell carcinomas, supporting the view that the latter do not arise from a germ cell progenitor. Bilateral OGCTs expressed more stem cell markers than unilateral cases. However, KIT was mutated in 5/13 unilateral dysgerminomas, whereas all bilateral dysgerminomas (n = 4) and all other histological types (n = 22) showed a wild type sequence. Furthermore, tissue from five phenotypic female patients harbouring combined dysgerminoma/gonadoblastoma expressed TSPY and contained Y-chromosome material as confirmed by FISH.ConclusionThis study provides new data supporting two distinct but overlapping pathways in OGCT development; one involving spontaneous KIT mutation(s) leading to increased survival and proliferation of undifferentiated oogonia, the other related to presence of Y chromosome material and ensuing gonadal dysgenesis in phenotypic females.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 17274819 · DOI · PMC1797189

Testicular cancer and antecedent diseases [3]

Research article Swerdlow AJ, Huttly SR, Smith PG · · 1987 · cited 73 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
A case-control study of the aetiology of testicular cancer was conducted using information obtained by interview and from case-notes of 259 cases with testicular cancer and two sets of control patients -238 men with diagnoses other than testicular cancer attending the same radiotherapy centres as those attended by the cases, and 251 hospital in-patients not attending radiotherapy departments.
Closing excerpt
The findings of associations with previous atopy and certain infections suggest a possible second aetiological mechanism - that immunological abnormalities may be associated with an increased risk of testis cancer.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (247 words)

A case-control study of the aetiology of testicular cancer was conducted using information obtained by interview and from case-notes of 259 cases with testicular cancer and two sets of control patients -238 men with diagnoses other than testicular cancer attending the same radiotherapy centres as those attended by the cases, and 251 hospital in-patients not attending radiotherapy departments. Logistic regression analyses were performed, after stratifying by age and region of residence, to estimate the relative risks (RRs) associated with various aspects of prior medical history. The risk of testicular cancer was found to be raised for men with a history of cryptorchidism (RR based on comparison with all controls = 6.3; P less than 0.001), inguinal hernia (RR = 1.6; P = 0.14), mumps orchitis (RR = 12.7; P = 0.006), atopy (RR = 1.8; P = 0.03), and meningitis (RR = 3.0; P = 0.21). Inguinal herniorrhaphy before the age of 15 years was particularly a risk factor for seminoma, whereas the relative risks were similar for seminoma and teratoma for the other factors. The results add to the growing evidence that congenital abnormalities involving the process of testicular descent and closure of the processus vaginalis are risk factors for testicular cancer, and that some types of testicular damage later in life may also be important. The findings of associations with previous atopy and certain infections suggest a possible second aetiological mechanism - that immunological abnormalities may be associated with an increased risk of testis cancer.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 2880604 · DOI · PMC2001571

Metastasizing dysgerminoma in an inland bearded dragon (Pogona vitticeps) [4]

Research article Schmidt-Ukaj S, Brunthaler R, Gumpenberger M · · 2024

Abstract reading summary — source excerpts
Opening excerpt
BackgroundMalignant dysgerminomas are infrequently reported ovarian neoplasms in animals, especially in exotic pets (non-traditional companion animals [NTCAs]).
Closing excerpt
ConclusionsThis report describes a case of malignant dysgerminoma with widespread intraosseous and visceral metastases in a captive inland bearded dragon (Pogona vitticeps).
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (219 words)

BackgroundMalignant dysgerminomas are infrequently reported ovarian neoplasms in animals, especially in exotic pets (non-traditional companion animals [NTCAs]). In the few published case reports on reptilian species, examples are primarily postmortem without antemortem (clinical) assessment.Patient presentationAn adult, 13-year-old, spayed female inland bearded dragon (Pogona vitticeps) presented with lethargy, a right-sided head tilt, unilateral exophthalmos and ventrotemporal strabismus on the right eye. On examination, a palpable mass (approximately 3.5 cm in diameter) was detected within the mid coelomic cavity. Computed tomography revealed a retrobulbar swelling and lytic bone lesions affecting the right frontal bone and several vertebrae (T11, T13, and T14). Multiple nodules of soft tissue opacity were also detected within the lungs, liver, and coelomic fat bodies. Haematology revealed leukocytosis with heterophilia and toxic granulation of heterophils. On the basis of these results, differential diagnoses included disseminated abscesses, granulomas (e.g., due to mycobacteriosis) and neoplasms. The lizard was subsequently euthanized due to end-stage disease and a poor prognosis. Postmortem gross examination and histopathology revealed a primary ovarian dysgerminoma with evidence of widespread metastasis as well as localized tissue destruction affecting the right retrobulbar space and frontal bone, the spinal column, the lungs, the liver, and both coelomic fat bodies.ConclusionsThis report describes a case of malignant dysgerminoma with widespread intraosseous and visceral metastases in a captive inland bearded dragon (Pogona vitticeps).

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 39633402 · DOI · PMC11619615

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Gonadoblastoma. A review of 74 cases [5]
    Scully RE · Cancer · 1970 · cited 383 times (Europe PMC)
  • Research article Gonadal and extragonadal germ cell neoplasia of childhood [6]
    Dehner LP · Hum Pathol · 1983 · cited 100 times (Europe PMC)
  • Research article Malignant potential of the dysgenetic gonad. Part 1 [7]
    Schellhas HF · Obstet Gynecol · 1974 · cited 99 times (Europe PMC)
  • Research article Central nervous system germinomas. A review [8]
    Horowitz MB, Hall WA · Arch Neurol · 1991 · cited 81 times (Europe PMC)
  • Research article Germ cell tumors of the thalamus and the basal ganglia [9]
    Tamaki N, Lin T, Shirataki K, Hosoda K, Kurata H, Matsumoto S, et al. · Childs Nerv Syst · 1990 · cited 64 times (Europe PMC)
  • Research article Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q [10]
    DeVore R, Whitlock J, Hainsworth JD, Johnson DH · Ann Intern Med · 1989 · cited 63 times (Europe PMC)

References

  1. Horwich A, Alsanjari N, A'Hern R, Nicholls J, Dearnaley DP, Fisher C. Surveillance following orchidectomy for stage I testicular seminoma. . 1992. PMID 1586607 · DOI · PMC1977398
  2. Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert-De Meyts E, Lothe RA. Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. . 2007. PMID 17274819 · DOI · PMC1797189
  3. Swerdlow AJ, Huttly SR, Smith PG. Testicular cancer and antecedent diseases. . 1987. PMID 2880604 · DOI · PMC2001571
  4. Schmidt-Ukaj S, Brunthaler R, Gumpenberger M. Metastasizing dysgerminoma in an inland bearded dragon (Pogona vitticeps). . 2024. PMID 39633402 · DOI · PMC11619615
  5. Scully RE. Gonadoblastoma. A review of 74 cases. Cancer. 1970. PMID 4193741 · DOI
  6. Dehner LP. Gonadal and extragonadal germ cell neoplasia of childhood. Hum Pathol. 1983. PMID 6343221 · DOI
  7. Schellhas HF. Malignant potential of the dysgenetic gonad. Part 1. Obstet Gynecol. 1974. PMID 4608181
  8. Horowitz MB, Hall WA. Central nervous system germinomas. A review. Arch Neurol. 1991. PMID 2039390 · DOI
  9. Tamaki N, Lin T, Shirataki K, Hosoda K, Kurata H, Matsumoto S, et al.. Germ cell tumors of the thalamus and the basal ganglia. Childs Nerv Syst. 1990. PMID 2178773 · DOI
  10. DeVore R, Whitlock J, Hainsworth JD, Johnson DH. Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q. Ann Intern Med. 1989. PMID 2648930 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Carcinoid TumorCancer and Oncology
  • ChordomaCancer and Oncology
  • ChoriocarcinomaCancer and Oncology
  • CraniopharyngiomaCancer and Oncology
  • Cutaneous Malignant MelanomaCancer and Oncology
  • Dermoid CystCancer and Oncology

All 107 articles in Cancer and Oncology →

At a glance

5,694
PubMed records on this heading
1%
published since 2020
413
review articles
12
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Carcinoid TumorCancer and Oncology
  • ChordomaCancer and Oncology
  • ChoriocarcinomaCancer and Oncology
  • CraniopharyngiomaCancer and Oncology
  • Cutaneous Malignant MelanomaCancer and Oncology

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support